Publications
2004
Asensi F, De Jose M, Lorente M, et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value in Health 2004;7(1):36-51.
Bergemann R, Huppertz E, Mueller E, Maxion-Bergemann S: Long-term Diabetes Complications: Influence of Delay in Starting Intensified Therapy and Patient Rates Treated to Target A1C. Analyses with the Diabetes Mellitus Model (DMM). In: ISPOR 7th European Congress, Oct. 24-26, 2004.
Bergemann R, Mueller E, Schwander: B, Cost Effectiveness of Capsule Endoscopy in diagnosing Obscure Gastrointestinal Bleeding in Germany, France, Switzerland, and the U.S. In: ICCE, 3rd ICCE, Miami, March 2004.
Casciano R, Tarride J-E, Breton MC, Stern L, Langer A. A pharmacoeconomic evaluation of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in Canada. Can J Clin Pharmacol 2004;11(1):e179-e90.
Chaves PHM, Mody SH, Najib MM, Siegartel LR, Blasi M, Woodman RC. Chronic, unexplained anemia in older African Americans. In: Annual Meeting of the American Geriatrics Society; 2004 May; Las Vegas; 2004.
Chaves PHM, Mody SH, Siegartel LR, Hill K, Woodman RC. Epidemiology of anemia in older adults. In: Annual Meeting of the American Society of Consultant Pharmacists; 2004 November; 2004.
Chaves PHM, Mody SH, Siegartel LR, Yektashenas B, Woodman RC. Chronic anemia in the elderly is associated with increased healthcare expenditures. In: Annual Meeting of the American Society of Consultant Pharmacists; 2004 November; 2004.
Chaves PHM, Mody SH, Siegartel LR, Yektashenas B, Woodman RC. Occurrence and clinical characteristics of unrecognized anemia in older adults. In: Annual Meeting of the American Society of Consultant Pharmacists; 2004 November; 2004.
Ciuryla V, Siegartel LR, Casciano R. Pharmacoeconomic evaluation of herd protection for the seven-valent pneumococcal conjugate vaccine in Switzerland. In: ISPOR 7th Annual European Congress; 2004 October; Hamburg, Germany; 2004.
Dharmarajan T, Norkus E, Mody S, et al. Chronic anemia in community-dwelling older adults is associated with an increase in falls and hip fractures. In: Annual Meeting of the American Geriatrics Society; 2004 May Las Vegas; 2004.
Katz LM, Stern LS, Fastenau JM, Piech CT, Doyle JJ. Acute myeloid leukemia in the elderly: Longitudinal outcomes and hospital charges in chemotherapy and non-chemotherapy patients. In: Annual Meeting of the American Society of Hematology; 2004 December; San Diego, California; 2004.
Katz LM, Stern LS, Fastenau JM, Piech CT, Doyle JJ. Trends in outcomes and charges of acute myeloid leukemia in the elderly: A cross-sectional analysis of the Nationwide Inpatient Sample from 1993 to 2001. In: Annual Meeting of the American Society of Hematology; 2004 December; San Diego, California; 2004.
Kierdorf HP, Wiggenhauser A, Sellen K, Freivogel K: Epoetin beta, administered with the multidose formulation Reco-Pen, is effective, safe and convenient for patients with renal anaemia. In: Kongress für Nephrologie 2004, Basel, September 18-21, 2004.
Kramer A, Daeschlein G, Kammerlander G, Andriessen A, Aspöck C, Bergemann R, Eberlein T, Gerngross H, Görtz G, Heeg P, Jünger M, Koch S, König B, Laun R, Peter RU, Roth B, Ruef C, Sellmer W, Wewalka G, Eisenbei§ W. Konsensusempfehlung zur Auswahl von Wirkstoffen für die Wundantiseptik. Zeitschrift für Wundheilung 2004, (3):110-120.
Müller E, Maxion-Bergemann S, Bolinder B, Gerber RA, Bergemann R: EAGLE - Economic Assessment of Glycemic control and Longterm Effects: A computer simulation model for diabetes mellitus Type 1 and Type 2. In: EASD Munich, Sep 5-9, 2004.
Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of a nebulized inhaled corticosteroid among elderly patients. In: The Gerontological Society of America's 57th Annual Scientific Meeting; 2004 November; Washington, DC; 2004.
Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: An assessment of outcomes. In: WONCA 2004: 17th World Conference of Family Doctors; 2004 October; Orlando, Florida; 2004.
Maxion-Bergemann, S, Huppertz E, Mueller E, Bergemann R, Clinical consequences of losing glycemic control: influence of two parameters of long-term diabetes complications - "delay in starting intensified therapy" and "rate of patients treated to target A1c". Incremental analyses with the Diabetes Mellitus Model. In: ADA 64th Annual Scientific Sessions Orlando, June 4-8, 2004.
Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Bergemann R: EAGLE-Diabetes Model: Basic features and internal validation of simulating long-term diabetic outcomes and related costs. In: ISPOR 7th European Congress, Oct. 24-26, 2004.
Mueller E, Schwander B, Bergemann R, Use of capsule endoscopy in diagnosing obscure gastrointestinal bleeding: cost-effectiveness evaluation from a European perspective. In: ISPOR 7th European Congress, Oct. 24-26, 2004.
Mueller E, Schwander B, Bergemann R. Cost-effectiveness evaluation for a new diagnostic test considering also costs for false negative and false positive diagnoses at various prevalence rates. In: ISPOR 7th European Congress, Oct. 24-26, 2004.
Mueller E, Schwander B, Bergemann R. Cost-effectiveness of Capsule Endoscopy in Diagnosing Obscure Gastrointestinal Bleeding from a European Perspective. In: ESMDM, European Society for Medical Decision Making 9th Biennial Conference, Rotterdam, June 6-8, 2004.
Mueller E, Schwander B, Bergemann R. Evaluation of cost-effectiveness for diagnostic tests when no gold standard is available in routine. In: ESMDM, European Society for Medical Decision Making 9th Biennial Conference, Rotterdam, June 6-8, 2004.
Mueller E, Schwander B, Bergemann R: Cost-Effectiveness of Capsule Endoscopy in Diagnosing Obscure Gastrointestinal Bleeding an International Comparison. In: Digestive Disease Week (DDW), New Orleans, May 15 - 20, 2004.
Olsson A, Casciano R, Stern L, Svangren P. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004;96(1):51-7.
Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: Findings from a retrospective analysis of Health plan data. J Urol 2004;171(6, Part 1 Of 2):2250-4.
Rosery H, Maxion-Bergemann S, Rosery B, Bergemann R. Ultraschall in der Schwangerschaft. Beurteilung der routinemäßigen Schwangerschaftsultraschalluntersuchungen unter Maßgabe der Mutterschaftsrichtlinien. HTA Schriftenreihe, Band 10, Hrsg.: Rüther, Dauben, Warda, Niebühl, 2004, ISBN 3-89906-733-9. http://gripsdb.dimdi.de/de/hta/hta_berichte/hta072_bericht_de.pdf
Siegartel LR, Mody SH, Piech CT, Doyle J, Woodman RC. Epidemiology and health resource utilization of anemia in elderly non-dialysis chronic kidney disease patients. In: National Kidney Foundation Clinical Meetings; 2004 April; Chicago, Illinoise; 2004.
Thielecke F, Maxion-Bergemann S, Abel F, Gonschior AK. Update in the pharmaceutical therapy of the irritable bowel syndrome. Int J Clin Pract. 2004 Apr;58(4):374-81.
Weiland O, Fried MW, Hadziyannis SJ, Foster GR, Messinger D, Freivogel K, Chaneac M: Combination Therapy With Peginterferon Alfa-2a (40KD) (PEGASYS¨) Plus Ribavirin (COPEGUS¨) in Treatment-Na•ve Patients With Chronic Hepatitis C and Genotype 1 Infection: Individual Estimated Probability of Sustained Virological Response (SVR). In: EASL, 39th Annual Meeting of the European Association for the Study of the Liver, Berlin, 2004.
Williams RT, O'Connell W, Walt JG, Siegartel LR, Katz LJ, Doyle JJ. Resource ultilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. In: ISPOR 7th Annual European Congress; 2004 October Hamburg, Germany; 2004.
2003
Bergemann R, Müller E, Maxion-Bergemann S, Walleser S, Cost of long-term outcomes and cost reduction with improved glycaemic control using the diabetes mellitus model (DMM). In: IDF 18th Congress, Paris, 24-29 August 2003.
Bergemann R, Müller E, Maxion-Bergemann S, Walleser S. Cost of long-term outcomes and cost saving with improved glycemic control using the diabetes mellitus model (DMM). In: ADA New Orleans, 2003.
Buller N, Gillen D, Casciano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia reduction with aggressive cholesterol lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003;21 (Suppl 1):25-32.
Casciano J, Amaya K, Doyle J, et al. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care Interface 2003;12(3):47-54.
Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Manag Care Interface 2003;(Suppl B):16-21.
Casciano R. Effectiveness measures of major depressive disorder in pharmacoeconomic evaluations. Manag Care Interface 2003;(Suppl B):14-5.
Chaves PHM, Mody SH, Najib MM, Siegartel LR, Blasi M, Woodman RC. Anemia in the elderly is associated with increased healthcare costs and resource utilization. In: Annual Meeting of the American Society of Hematology; 2003 December 6-9; San Diego; 2003.
Chaves PHM, Mody SH, Najib MM, Siegartel LR, Hill K, Woodman RC. Clinical epidemiology of anemia in older adults. In: Abstract Issue of Blood; 2003 November; 2003.
Hauner H, Maxion-Bergemann S, Müller E, Schulz M, Huppertz E, Bergemann R. [Disease management program (DMP) diabetes mellitus: simulation of therapeutic results of different guidelines. A new diabetes mellitus model (DMM)] Dtsch Med Wochenschr. 2003 May 23;128(21):1167-72.
Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003;63(24):8749-56.
Lebel MH, Kellner JD, Ford-Jones EL, et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003;36(3):259-68.
Müller E, Walleser S, Maxion-Bergemann S, Bergemann R. Effect of improved glycemic control on the incidence of diabetic end stage renal disease in the United States: an analysis using the Diabetes mellitus Model. In: ISTAHC Canmore, 2003.
Müller E, Walleser S, Maxion-Bergemann S, Bergemann R. Simulation of micro- and macrovascular outcomes in a Type 2 diabetes population using the Diabetes Mellitus Model: effect of improved glycaemic control. In: IDF 18th Congress, Paris, 24-29 August 2003.
Müller E, Walleser S,. Maxion-Bergemann S, Bergemann R. The Diabetes Mellitus Simulation Model: Model Structure, Validity and applications. In: ISTAHC Canmore, 2003.
Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 2003;15(4):385-98.
Maxion-Bergemann S, Müller E, Bergemann R, Walleser S, Huppertz E . Improved Glycaemic Control and Less Hypoglycemia with Insulin Glargine Compared with NPH Insulin in Patients With Type 2 Diabetes Leads to Fewer Long-Term Complications - Results of the Diabetes Mellitus Simulation Model. In: ISPOR. 6th Annual European Congress, Barcelona 9-11 Nov 2003.
Moul JW, Penson DF, Evans CP, et al. Metastatic progression rates after initial treatment for prostate cancer: Data from a Midwestern health care system. In: Annual Meeting of the American Urological Association; 2003 April; 2003.
Mueller E, Maxion-Bergemann S, Huppertz E, Bergemann R. Modeling of Treatment Guidelines: German Diabetes Disease Management Programs and Results from the Diabetes Mellitus Model (DMM) . In: 25th Annual SMDM Meeting. Chicago 2003.
Najib MM, Doyle J, Katz LM, Fastenau JM, Rosenblatt LC. Costs and epidemiology of myelosuppression in chemothereapy-treated metastatic breast cancer patients. In: Annual Meeting of the American Society of Hematology; 2003 December; San Diego, California; 2003.
Neugut AI, Moul JW, Penson DF, et al. PSA progression rates after initial treatment for prostate cancer: Data from a Midwestern health care system. In: American Society of Clinical Oncology; 2003 June; 2003.
Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic prostate cancer progression: Findings from a retrospective analysis of health plan data. In: American Urological Association 2003 Annual Meeting; 2003 April 26 - May 1; Chicago, Illinoise; 2003.
Penson DF, Moul JW, Evans CP, et al. The economic burden of PSA progression in prostrate cancer: Findings from a retrospective analysis of health plan data. In: Annual Meeting of the American Society of Clinical Oncology; 2003 June; Chicago; 2003.
Piper C, Bergemann R, Schulte HD, Koerfer R, Horstkotte D. Can progression of valvar aortic stenosis be predicted accurately? Ann Thorac Surg. 2003 Sep;76(3):676-80; discussion 680.
Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis International 2003; 14(10):801-7.
Rosery H, Bergemann R: Regulatory Gaps in Reimbursement of Ventricular Assist Devices in Germany. In: 11th Congress of the International Society for Rotary Blood Pumps (ISRBP). Bad Oeynhausen, Germany. August1st - September 2nd, 2003.
Rosery H, Schmidt E, Bergemann R: Derivation of Cost Data in Patients with Rheumatoid Arthritis. In: International Conference ÒHealth Economics in RheumatologyÓ. April 2003. Mayo Clinic, Rochester, Minnesota, USA.
Rosery H, Schwander B, Bergemann R: Identification of Unit Costs in Rheumatoid Arthritis. Research Approach and Results. In: ISPOR. 6th Annual European Congress, Barcelona 9-11 Nov 2003.
Rosery H. Daily cost of four different classes of antihypertensive agents in Germany. In: ISTAHC Canmore, 2003.
Rosery H: Reimbursement of Ventricular Assist Devices - Status Quo and Quo Vadis. In: 3rd Berlin Symposium. Technical Circulatory Support. Berlin, Germany. November 22-23, 2003.
Sander B, Bergemann R. Economic burden of obesity and its complications in Germany. Eur J Health Econ. 2003 Nov;4(4):248-53.
Sander B, Gyldmark M, Bergemann R, Garrison L: Post-exposure influenza prophylaxis with Oseltamivir: Cost-effectiveness and cost-utility in families in the UK. In: ISPOR. 6th Annual European Congress, Barcelona 9-11 Nov 2003.
Sander B, Gyldmark M: Introduction of a new health technology, potential behavioural and organisational changes and policy impact - assessment of new influenza treatments. In: ISPOR. 6th Annual European Congress, Barcelona 9-11 Nov 2003.
Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology 2003;110(7):1412-9.
Schwartz G, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. AJC 2003;92:1109-12.
Traverso CE, Gandolfi SA, Kelly SP, et al. Estimation of resource utilization associated with glaucoma disease progression in a multinational retrospective study in Europe. In: Annual Meeting of the American Academy of Ophthalmology; 2003 November 16-18; Anaheim, California; 2003.
Walleser S, Maxion-Bergemann S, Müller E, Bergemann R. Costs of diabetic end stage renal-disease in the United States and potential cost savings with good glycemic control: an analysis using the Diabetes Mellitus Model and USRDS cost data. In: IHEA San Francisco, 2003.
Walleser S, Maxion-Bergemann S, Müller E, Bergemann R. Effect of long-term response to glycemic control treatment on diabetic blindness, end-stage renal disease and amputation in a type 2 diabetes population: an analysis using the diabetes mellitus model. In: ADA New Orleans, 2003.
Walleser S, Maxion-Bergemann S, Müller E, Bergemann R. Effect of long-term response to glycemic control treatment on diabetic blindness, end-stage renal disease and amputation in a type 2 diabetes population: an analysis using the diabetes mellitus model. In: IDF 18th Congress, Paris, 24-29 August 2003.
2002
Bergemann R, Bolinder B, Maxion-Bergemann S., Improvement of HbA1c control and prediction of long-term complication rate in diabetes mellitus type 1: Simulation of three European populations with Markov-Simulation model. In: EASD Budapest August, 2002.
Bergemann R. Carrel T, Maxion-Bergemann S., Potential Cost Savings in Switzerland due to the Usage of Off-Pump Surgery, Cost Comparison Analysis for Off-Pump Surgery for Switzerland. In: IISTAHC Berlin, July 2002.
Casciano J, Arikian S, Doyle J, et al. Economic analysis of therapies for onychomycosis of the toenails and fingernails. In: World Congress of Dermatology 2002 June; Paris, France; 2002.
Casciano R, Doyle JJ, Chen J, et al. Economic benefits of amlodipine treatment in patients with coronary artery disease. Pharmacoeconomics 2002;20(8):553-63.
Casciano R, Doyle JJ, McGuire A, et al. The cost-effectiveness of Amlodipine treatment in patients with coronary Artery Disease in the U.K. British Journal of Cardiology 2002;9(2).
Doyle J, Amaya K, Casciano J, Kotak S, Buchholz P, Walt J. A disease severity staging system for measuring the cost of glaucoma progression in Europe. In: ISPOR 2002 5th Annual European Congress; 2002; Rotterdam, The Netherlands; 2002.
Doyle J, Amaya K, Casciano J, Kotak S, Buchholz P, Walt J. A disease severity staging system for measuring the cost of glaucoma progression in Europe. Value in Health 2002;5(6):552. Abstract.
Doyle J. Developing glaucoma treatment recommendations. Supplement to Ophthalmology Management 2002.
Doyle JJ, McGuire A, Arocho R, et al. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. Int J Clin Pract 2002;56(2):76-81.
Doyle JJ, McGuire A, Arocho R. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. International Journal of Cardiology 2002;84:23-30; discussion -2.
Doyle JJ, Thaulow E, Jorgensen B, et al. Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis. British Journal of Cardiology 2002;9(1):31-6.
Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002;15(11):28-36.
Lee PP, Budenz DL, Chen PP, et al. A multi-center, retrospective study of resource utilization associated with severity of disease in glaucoma. In: American Academy of Ophthalmology/Pan American Academy of Ophthalmology (AAO/PAOO) Joint Meeting 2002; 2002; Orlando, Florida; 2002.
Limentani S, Chin L, Casciano J, Casciano R, Evans S, Lebovics G. Carmustine implants for glioma cost-effective compared with other innovative oncology treatments. Oncology 2002;11(6):33-4.
Maxion-Bergemann S, Wittenberg W, Bergemann R. Long-term consequences for the treatment of hypertensive diabetes type 2 patients with a fixed combination of an ace-inhibitor and non-dihydropyridine-calcium-channel-blocker in comparison to other combination therapies. In: ISPOR Fifth Annual European Congress, Rotterdam, 2002.
Mills R, Bundenz D, Lee P, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage diseaseby a novel six point system. In: Assocation for Research in Vision Ophthalmology (ARVO); 2002 May; Fort Lauderdale, Florida; 2002.
Mueller E, Maxion-Bergemann S, Bergemann R. Long-term effective HbA1c control reduces the incidence of late diabetic complications. Simulation results from the DMM. In: ISTAHC annual meeting, Berlin, 2002.
Mueller E., Maxion-Bergemann S., Gultyaev D. Bergemann R., Diabetic complications depending on HbA1c values and treatment response in a simulation cohort of type 1 and type 2 diabetic patients. Results from the Diabetes Model. In: 24th Annual Meeting of the Society for Medical Decision Making, Baltimore, USA, 2002.
Muller E., Maxion-Bergemann S., Bergemann R., Das Diabetes Mellitus Simulationsmodell (DMM): Modellstruktur, Validität und Anwendungsmöglichkeiten. In: DAE-GMDS Jahrestagung, Berlin, 2002.
Piper C, Hetzer R, Körfer R, Bergemann R, Horstkotte D. The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation. Eur Heart J. 2002 Jan;23(1):79-86.
Ringe JD, Dorst A, Sorenson F. Determination of response to ibandronate intravenous injections, given every 3 months, versus alfacalcidol in corticosteroid-induced osteoporosis patient subgroups using a novel algorithm. In: EULAR meeting - European League Against Rheumatism, June 12-15, 2002.
Ringe JD, Dorst A, Sorenson F. Intravenous ibandronate injection every 3 months is superior to oncedaily oral alfacalcidol in the treatment of corticosteroid-induced osteoporosis, irrespective of gender. In: 3rd International Symposium on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, Barcelona Nov 6-9, 2002.
Rosery H, Hense HW. Implication of different hypertension guidelines on cost and cost-effectiveness- an empirical comparison. In: ISTAHC Berlin, July 2002.
Rosery H, Hense HW. Influence of three hypertension guidelines on rates of treatment indication. In: ISPOR Fifth Annual European Congress, Rotterdam, 2002.
Sander B, Gyldmark M, Morris J, Bergemann R. Influenza treatment with oseltamivir in a high risk population-a cost-effective option for the health care payer. In: ISPOR Fifth Annual European Congress, Rotterdam, 2002.
Sander B, Gyldmark M, Morris J, Mueller E, Bergemann R. Influenza treatment with oseltamivir in an otherwise healthy adult population - a cost-effective option for the health care payer. In: 24th Annual Meeting of the Society for Medical Decision Making, Baltimore, USA, 2002.
Sander B, Thieme M, Kühnel U. Cost-effectiveness of influenza prophylaxis with a new nasal vaccine in Switzerland. In: First European Influenza Conference, St.-Julians, Malta, 2002.
Sander B., Gyldmark M., Morris J., Bergemann R. Influenza treatment with oseltamivir: costs and benefits for the individual as well as for the society. Int J Antimicrob Agents 19 [Supplement 1], S22-S23. 7-5-2002.
Serle J, Cantor L, Gross R, et al. Best practice treatment algorithm for primary open-angle glaucoma: implications for US ophthalmology practice. Manag Care Interface 2002;15(7):37-48.
Thaulow E, Jorgensen B, Doyle JJ, et al. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int J Cardiol 2002;84(1):23-30; discussion -2.
Trivedi M, Casciano R, Wan GJ, Mallick R, Chen J, Geissler E. Cost and effectiveness of venlafaxine extended-release and SSRI treatment for major depression: Workplace implications. Pharmacotherapy 2002;22(10):1359. Abstract.
Trivedi M, Casciano R, Wan GJ, Mallick R, Chen J, Geissler EC. Cost and effectiveness of venlafaxine extended-release and SSRI treatment for major depression: Clinical implications. In: Academy of Managed Care Pharmacy Educational Conference; 2002 October 9-12; Washington, DC; 2002.
Trivedi M, Casciano R, Wan GJ, Mallick R, Chen J, Geissler EC. Cost and effectiveness of venlafaxine extended-release and SSRI treatment for major depression: Clinical implications. Journal of Managed Care Pharmacy 2002;8(5):418-9. Abstract.
Van de Putte L, Bergemann R, Rosery H, Pang F, Dietz B, Kupper H, Ashraf T. Variation in resource utilization and treatment costs for rheumatoid arthritis (RA) across 5 countries in an adalimumab (D2E7) clinical trial. In: ISPOR Fifth Annual European Congress, November 2002.
Van de Putte L, Boggs R, Sengupta N, Dietz B, Bergemann R, Rosery H, Kupper H. Improvement in the health utility among rheumatoid arthritis (RA) patients treated with adalimumab (D2E7), a fully human anti-TNF monoclonal antibody. In: ISPOR Fifth Annual European Congress, Rotterdam, 2002.
Walt J, Doyle J, Casciano J, Evans S, Kotak S. The development of a severity staging system for economic of the progression of glaucoma. In: ISPOR; 2002 May; Arlington, Virginia; 2002.
2001
Arikian SR, Gorman JM. A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders. Prim Care Companion J Clin Psychiatry 2001;3(3):110-7.
Babin-Ebell J, Schuster C, Elert O, Bergemann R, Horstkotte D and the GELIA Study Group: Influence Influence of valve size on morbidity and mortality for patients with mechanical valve replacements (GELIA 8). Eur Heart J Suppl 2001; 3: Q73-Q77.
Bergemann R, Mueller E. Economic outcomes after heart valve replacement surgery in Germany. Eur Heart J Suppl 2001; 3: Q70-Q72.
Bergemann R, Suissa S, Morris A, Dineen S, Hauner H. A Simulation Model for Diabetes Mellitus Type I and II: Model Description and Internal Validation Process with UKPDS, DCCT, AND WESDR data. In: EASD Glasgow, September 2001.
Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: A multinational study. Int J Clin Prac 2001;55(5):292-9.
Casciano J, Doyle J, Casciano R, et al. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. Int J Clin Pract 2001;55(2):84-92.
Doyle J, Omvik P, Arikian S, et al. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface 2001;14(3):82-7.
Doyle J, White TJ, Tran MH, Casciano R, Stern L. Economic impact of aggressive lipid lowering with atorvastatin on early recurrent ischemic events in acute coronary syndromes. In: 36th Annual ASHP Mid-year Clinical Meeting and Exhibts; 2001 December 2-6; 2001. p. 3 Posters.
Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health 2001;4(1):16-31.
Horstkotte D, Bergemann R. Thrombogenicity of the St. Jude medical prosthesis with and without silzone-coated sewing cuffs. Ann Thorac Surg. 2001 Mar;71(3):1065.
Mueller E, Bergemann R, GELIA Study Group. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7). Eur Heart J Suppl 2001; 3: Q65-Q69.
Mueller E, Sturmer T, Brenner H. Alcohol intake and high density lipoprotein-cholesterol: comparison of food frequency questionnaire and diet record in a general population sample. J Epidemiol Biostat 2001; 6(3):297-303.
Mueller E, van Leen MW, Bergemann R. Economic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers. Pharmacoeconomics 2001; 19(12):1209-1216.
Neugut A, Vredenburgh J, Weisberg J, et al. Relative efficacy and cost-effectiveness analysis (CEA) of docetaxel versus paclitaxel in treatment of metastic breast cancer (MBC). In: American Society of Clinical Oncology; 2001; 2001.
Schiffman R, Smith JA, Walt J, Jacobsen G, Doyle J, Lebovics G. Utility assessment among patients with dry eye disease. In: American Academy of Opthalmology; 2001 November 13; New Orleans, Louisiana; 2001.
Seebacher C, Bergemann R. Nosokomiale Infektionen durch Pilze. In: Kramer A, Heeg P, Botzenhart K, eds. Krankenhaus- und Praxishygiene. 1st ed. Urban & Fischer:München, 2001:4-148.
Thaulow E, Jorgensen B, Doyle JJ, et al. A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Cardiovasc Manag 2001;12(2):31-5.
Walt JG, Doyle J, Jacobsen G, Lebovics G, Schiffman R. MD utility assessment among patients with dry eye disease. In: American Academy of Ophthalmology; 2001 November; New Orleans, Louisiana; 2001.
Walt JG, Schiffman R, Evans S, Lebovics G. Utility assessment among patients with dry eye disease. In: ISOQOL - 8th Annual meeting; 2001 November; Amsterdam, The Netherlands; 2001.
2000
Arikian S. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clin Ther 2000;22(4):494-6.
Arikian S, Casciano J, Kang-Cipolla L, et al. The management of depression: The implications for managed care--roundtable discussion: Part 2. Manag Care Interface 2000;(Suppl B):19-25, 32.
Arikian SR, Casciano J, Doyle JJ, Casciano R, Kim R. A pharmacoeconomic analysis of doxazosin for the treatment of hypertension in diabetic patients in Italy. In: ESH 2000 June; Gšteborg, Sweden; 2000.
Arikian SR, Casciano JP, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13(2):88-94.
Arikian SR, Ciuryla V, Doyle JJ, Casciano J, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. In: ISPOR 2000 May; Arlington, Virginia; 2000.
Arikian SR, Ciuryla V, Doyle JJ, Casciano J, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. Value in Health 2000;3(2):121-2.
Arikian SR, Ciuryla V, Doyle JJ, et al. A multinational pharmacoeconomic evaluation of the pneumococcal conjugate vaccine. In: ESPID 2000 May; Amsterdam, The Netherlands; 2000.
Arikian SR, Ciuryla V, Wang E, Casciano R, Krishnaswamy R, Hvidsten K. An economic evaluation of the seven-valent pneumococcal conjugate vaccine in Canada. In: 4th Canadian National Immunization Conference (CNIC); 2000 December; Halifax, Nova Scotia, Canada; 2000.
Casciano J, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. In: ISPOR; 2000 May; Arlington, Virginia; 2000.
Casciano J, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. Value in Health 2000;3(2):80.
Casciano J, Doyle J, Amaya K. Setting reimbursement policy with cost-effectiveness analysis for the treatment of patients with glioblastoma multiform. Managed Care & Cancer 2000;2(2):16-22.
Casciano J, Doyle JJ, Casciano R, et al. Cost-effectiveness of doxazosin in combination therapy for hypertension treatment in diabetic patients in the U.K. In: ISPOR; 2000 November; Antwerp, Belgium; 2000.
Casciano R. Economic analysis of the cost of uncontrolled hypertension in the United States. In: Medical Science Liaison Training; 2000 October; Los Angeles, California; 2000.
Casciano R, Arikian SR, Tarride JE, Casciano J, Doyle JJ. Antidepressant selection for major depressive disorder: The budgetary impact on managed care. Behavioral Health Trends 2000;12:6-17.
Casciano R, Gallagher P. Valuation & early drug discovery - ÒPortfolio management for the biotech industryÓ. In: Barnett Portfolio Conference; 2000 October; San Diego, CA; 2000.
Doyle JJ, Arikian SR. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. In: FIGO; 2000 September; Washington, D.C.; 2000.
Doyle JJ, Arikian SR, Casciano J, Casciano R, Baleeva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. In: ISPOR; 2000 May; Arlington, Virginia; 2000.
Doyle JJ, Arikian SR, Casciano J, Casciano R, Baleeva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. Value in Health 2000;30(2):100.
Doyle JJ, Arikian SR, Casciano J, Casciano R, Gonzalez M, Kopp Z. A cost comparison study of amlodipine and enalapril in the treatment of hypertension in Europe. In: ISPOR; 2000 November; Antwerp, Belgium; 2000.
Doyle JJ, Evans S. Health economics in end stage glaucoma. In: End Stage Glaucoma Advisory Board Meeting, Assocation for Research in Vision Ophthalmology (ARVO) 2000 April; Fort Lauderdale, Florida; 2000.
Flack JM, Doyle J, Casciano R, Arocho R, Casciano J, Gonzalez M. The health economic impact of failure to reach blood pressure goals. Am J Hypertension 2000;13:17A-9A.
Flack JM, Doyle JJ, Casciano R, Arocho R, Casciano J, Gonzalez M. The health economic impact of failure to reach blood pressure goals. In: ASH; 2000 May; New York, New York; 2000.
Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000;18(2):143-8.
Horstkotte D, Bergemann R, Geiger A, Huth C , Hutschenreiter W, Oelert H, Laas J, Mohr FW and the GELIA Study Group. Thromboembolism and bleeding in patients with St. Jude Medical heart valve prostheses: interim results of the GELIA study. In: 3rd Joint Meeting of the German, the Austrian and the Swiss Societies for Thoracic and Cardiovascular Surgery, Luzern, Switzerland, Feb 9-12, 2000. Thorac Cardiovasc Surg. 2000;48:1103.
Piper C, Bergemann R, Schulte HD, Körfer R, Horstkotte D. [Is the estimation of the progression of valvular aortic stenosis possible?] Dtsch Med Wochenschr. 2000 Apr 20;125(16):484-8.
1999
Arikian SR, Casciano J, Doyle JJ. Evaluating your decisions, portfolio decision-making outcomes. In: Biopharm Conference 1999 June; Philadelphia, Pennsylvania; 1999.
Arikian SR, Casciano RN, Casciano JP, Doyle JJ. Emerging therapeutic options for overactive bladder: the economics of medicare populations in managed care. In: AMCP 1999 April - May; Minneapolis, Minnesota; 1999.
Arikian SR, Doyle JJ. Portfolio valuation & brand economics. In: Barnett Portfolio Conference 1999 November; Philadelphia, Pennsylvania; 1999.
Arikian SR, Tarride J-E, Casciano R, Casciano J. Determining cost drivers in a cost-effectiveness analysis of three treatments for overactive bladder. In: ISPOR; 1999 May; Arlington, Virginia; 1999.
Arikian SR, Tarride J-E, Casciano R, Casciano J. Determining cost drivers in a cost-effectiveness analysis of three treatments for overactive bladder. Value in Health 1999;2(3):152.
Bergemann R, Lauterbach KW, Vanscheidt W, Neander KD, Engst R. Economic evaluation of the treatment of chronic wounds: hydroactive wound dressings in combination with enzymatic ointment versus gauze dressings in patients with pressure ulcer and venous leg ulcer in Germany. Pharmacoeconomics. 1999 Oct;16(4):367-77.
Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 1999;13 (Suppl A):89A-96A.
Camara E, Miyashiro J, Wong L, Grogg A, Arikian SR. Medical resource utilization in schizophrenia: A comparative analysis of risperidone and haloperidol in a VA population. In: APA; 1999 May; Washington, DC; 1999.
Casciano J, Arikian S, Tarride JE, Doyle JJ, Casciano R. A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiol Psichiatr Soc 1999;8(3):220-31.
Casciano R, Arikian SR, Casciano J, Doyle JJ. Estimating patient level efficacy rates using data expressed at the population level. In: International Conference on Health Policy Research; 1999 December; Santa Monica, California; 1999.
Casciano R, Arikian SR, Tarride J-E, Doyle JJ. A method for comparing disparate outcome measures in trials of urinary incontinence: Controlled release oxybutynin versus tolterodine. In: ISPOR; 1999 May; Arlington, Virginia; 1999.
Doyle JJ, Arikian SR, Amsel A, Casciano R. A cost comparison study of amlodipine and enalapril as treatment for hypertension in the United States. In: ISPOR; 1999 November; Edinburgh, Scotland; 1999.
Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther 1999;21(2):296-308.
Frost F, Hurley JS, Petersen HV, Casciano RN. Estimated incidence of Clostridium difficile infection. Emerg Infect Dis 1999;5(2):303-4.
Kramer A, Bergemann R, Bruck J, Kammerlander G, Metelmann H-R, Roth B. Indikationen und Auswahlkriterien für lokale Wundantiinfektiva und Wundauflagen im Rahmen der chirurgischen Wundbehandlung. In: Beck E, Eikmann T, editors. Hygiene in Krankenhaus und Praxis. Loseblattsammlung. Landsberg: ecomed; 1999, 1-16.
Haller L, Sossouhounto R, Coulibaly IM, Dosso M, Kone M, Adom H, Meyer UA, Betschart B, Wenk M, Haefeli WE, Lobognon LR, Porquet M, Kabore G, Sorenson F, Reber-Liske R, Sturchler Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy 1999;45(6):452-65.
1998
Arikian SR, Casciano J, Doyle JJ. Multinational pharmacoeconomics of major depressive disorders. In; 1998 September; Copenhagen, Denmark; 1998.
Arikian SR, Casciano J, Doyle JJ. Multinational health economics of major depressive disorders. In; 1998 July; Glasgow, Scotland; 1998.
Arikian SR, Casciano J, Doyle JJ. Computer assisted decision analytic modeling. In: ISPOR 1998 May; Philadelphia, Pennsylvania; 1998.
Arikian SR, Casciano J, Doyle JJ. Multinational pharmacoeconomics analysis of major depressive disorders from the prospective of the National Health Service. In; 1998 March; Edinburgh, Scotland; 1998.
Arikian SR, Casciano J, Doyle JJ. Pharmacoeconomics of major depressive disorders. In: Drug Information Association 1998 February; London, United Kingdom; 1998.
Arikian SR, Doyle JJ, Closon M-C, Tarride J-E. A health economic evaluation of HRT in Belgium. In: ISPOR; 1998 December; Cologne, Germany; 1998.
Arikian SR, Einarson T, Casciano J, Doyle JJ. The budget impact of pharmacotherapy selection for major depressive disorder: A multinational study. In: ISPOR; 1998 December; Cologne, Germany; 1998.
Arikian SR, Einarson T, Casciano J, Doyle JJ. The budget impact of pharmacotherapies for major depression. In: ASHP; 1998 December; Las Vegas, Nevada; 1998.
Arikian SR, Einarson T, Casciano J, Doyle JJ. A health policy analysis of pharmacotherapy for major depressive disorder in Europe and the Americas. In: European College of Neuropsychopharmacology Congress (ECNP); 1998 October; Paris, France: Value in Health, 1998;1 (1):78; 1998.
Doyle J, Sinha N. Economics of ifosfamide-based chemotherapy in the outpatient setting. Cancer Management 1998;3(2).
Horstkotte D, Piper C, Wiemer M, Arendt G, Steinmetz H, Bergemann R, Schulte HD, Schultheiss HP. [Emergency heart valve replacement after acute cerebral embolism during florid endocarditis] Med Klin (Munich). 1998 May 15;93(5):284-93.
Horstkotte D, Bergemann R, Oelert H, Schulte HD, Laas J, Zerkowski HR. [Increased acceptance of the International Normalized Ratio (INR) as a monitoring parameter of oral anticoagulation therapy in Germany. GELIA Study Group] Z Kardiol. 1998 Oct; 87(10):837-43.
Shear NH, Einarson TR, Arikian SR, Doyle JJ, van Assche D. Pharmacoeconomic analysis of topical treatments for tinea infections. Int J Dermatol 1998;37(1):64-71.
Sinha N, Hainsworth JD, Einarson TR, Doyle JJ, Arikian SR, Lappas PT. A health-economic evaluation of paclitaxel and carboplatin versus vinorelbine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. Value in Health 1998;1(1):71.
1996
Arikian SR, Doyle JJ, Markison B. Medicine joins the information highway. Medical Marketing and Media 1997.
Arikian SR, Einarson TR, Doyle JJ. Economic evaluation of treatments for eczema and atopic dermatitis. Care Management Skin Disease 1997;23:317-40.
Arikian SR, Mario GG, Doyle JJ. Building a computerized disease management operating system. Oncology (Huntingt) 1996;10(Suppl 11):223-32.
Bergemann R., Kirchhof B: Sind Life Years Gained (LYG) gleich LYG? Die Auswirkungen unterschiedlicher Methoden auf Kosten-Effektivitätsanalysen, Gesundheitsökonomie und Qualitätsmangement, 1996, p 21-26.
Bergemann R., Kosten und Nutzen verschiedener Behandlungsstrategien bei chronischen Wunden. Grundzüge effektiver Wundbehandlung in Klinik und Praxis. Dorint Hotel, Potsdam, Feb 1998.
Bergemann R., Wirtschafltichkeit verschiedener Behandlungsstrategien bei chronischen Wunden, Fortbildungsveranstaltung der Landesärztekammer Schleswig-Holstein, Bad Segeberg, Sept 1998.
Doyle J, Dhanani S, Lappas P. Health economic evaluation of high dose therapy with a CBV regimen in relapsed or refractory Hodgkin's Disease. In: The IBMTR/ABMTR 1997 Annual Participants Meeting; 1997 February; 1997.
Doyle JJ, Casciano JP, Arikian SR, Mauskopf J, Paul JE. Full-cost determination of different levels of care in the intensive care unit. An activity-based costing approach. Pharmacoeconomics 1996;10(4):395-408.
Doyle JJ, Dezii CM, Sadana A. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer. Semin Oncol 1996;23(6 Suppl 13):51-60.
Einarson TR, Gupta AK, Shear NH, Arikian S. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996;9(4):307-20.
Grove AK, Bergemann R, Keller R. Preventive Treatment of chronic Bronchitis: a cost-effectiveness analysis for an immunoactive bacterial extract in Switzerland. The British Journal of Medical Economics 1996 10: 1-14.
Hasselmann M, Kummerlen CH, Bryg, DJ, Pasquali JL, Bourguignat A, Altieri M, Tulasne PA, Sauder PH, Martinet O, Pinto L, Lutun Ph. Enteral feeding supplemented with arginine, fish oil and nucleotides (IMPACT¨) reduces infection rate and improves immunitary status in critically ill patients. Intensive Care Med 1997.
Horstkotte D., Bergemann R., Laas J., Schulte HD, Mohr FW, Zerkowski HR, GELIA-Studiengruppe: Thromboembolism and Bleeding in Patients with St.Jude Medical Heart Valve Prostheses: Interim Results of the GELIA Study. In: 71st American Heart Association Scientific Session in Dallas, Nov 1998.
Kummerlen Ch, Hasselmann M, Pasquali JL, Bryg DJ, Tulasne PA, Altieri, Sauder Ph, Bourguignat, Martinet. Does the initial immune status influence the immuno9logic effects and the infection rate in critically ill patients fed with an enteral nutrition formula enriched with arginine, fish oil and nucleotides (IMPACT¨). Clinical Nutrition 1997.
McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997;15(2):640-5.
Murad A, Andrade CA, Delfino C, et al. Pharmacoeconomic evaluation of Tegafur-Uracil (UFT) vs Fluorouracil for the management of colorectal cancer in Brazil and Argentina. Clinical Drug Investigators 1997;2:90-8.
Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America. Oncology (Huntingt) 1997;11(9 Suppl 10):128-35.
1995
Arikian SR, Einarson TR, Doyle JJ. Cost-effectiveness analysis of available sclerosis agents used for pleurodesis in the management of malignant pleural effusion. In: Program/Proceedings of the American Society of Clinical Oncology; 1995 May; 1995.
Arikian SR, Suver J, Einarson T, Doyle JJ. Economic and quality of life outcomes: the four-step pharmacoeconomic research model. Oncology (Huntingt) 1995;9(Suppl 11):33-6.
Belani C, Einarson TR, Arikian SR, Doyle JJ. Cost-effectiveness analysis of pleurodesis in the management of malignant pleural effusion. J Oncol Manag 1995;4:24-34.
Belani C, Einarson TR, Arikian SR, Doyle JJ. Cost-effectiveness analysis of available sclerosis agents used for pleurodesis in the management of malignant pleural effusion. In: Program/Proceedings of the American Society of Clinical Oncology; 1995 May; 1995.
Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995;17(1):136-53.
Einarson TR, Arikian SR, Doyle JJ. Rank-order stability analysis (ROSA): testing pharmacoeconomic data. Med Decis Making 1995;15(4):367-72.
Einarson TR, Arikian SR, Doyle JJ, Shear N. Pharmacoeconomic analysis of oral treatments for onychomycosis: A Canadian study. J Res Pharm Econ 1995;6:3-22.
Shear NH, Einarson TR, Arikian SR, Doyle JJ. Pharmacoeconomic analysis of topical treatments for tinea infections. Pharmacoeconomics 1995;7(3):251-67.
Shear NH, Einarson TR, Arikian SR, Doyle JJ, van Assche D. Therapie von Tinea-Infektionen: Eine pharmacoeckookonomische Analyse der topischen Terapie in Osterreich, Deurschland und der Schweiz. Z. Allg Med 1995;71:1055-60.
Suver J, Arikian SR, Doyle JJ, Sweeney SW, Hagan M. Use of anesthesia selection in controlling surgery costs in an HMO hospital. Clin Ther 1995;17(3):561-71; discussion 16.
Suver JD, Arikian SR, Shannon MC, Doyle JJ, Sweeney SW. A multifactorial approach to understanding anesthesia selection. Health Care Manage Rev 1995;20(3):7-15.
1994
Arikian SR, Einarson TR. The annual cost of psoriasis. J Am Acad Dermatol 1994;30(6):1047-8.
Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The onychomycosis study group. Br J Dermatol 1994;130 (Suppl 43):35-44.
Arikian SR, Suver J, Doyle JJ, Sweeney SW. The pathways study: an analysis of the net economic impact of anesthesia selection of the total cost of surgery: results of an economic clinical trial comparing propofol to thiopental/insoflurane. In: Program/Proceedings of the American Society of Hospital Pharmacists Annual Meeting; 1994 December; 1994.
Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130 (Suppl 43):32-4.
Olsen A, Arikian SR. The promises and pitfalls of pharmacoeconomic studies. Medical Marketing and Media 1994;29(11).
1993
Arikian SR. Getting the most out of pharmacoeconomics. Healthc Exec 1993;8(5):45.
Einarson TR, Arikian SR, Near N. Oral treatments for severe psoriasis: government payor analysis for Canada. Journal of Dermatology Treatment 1993;4:S23-S7.
1992
Arikian S. The nuts & bolts of pharmacoeconomic trials. Medical Marketing and Media 1992.